PropertyValue
?:abstract
  • COVID-19, the human coronavirus disease caused by SARS-CoV-2, was reported for the first time in Wuhan, China in late 2019. COVID-19 has no preventive vaccine or proven standard pharmacological treatment, and consequently, the outbreak swiftly became a pandemic affecting more than 215 countries around the world. For the diagnosis of COVID-19, the only reliable diagnostics is a qPCR assay. Among other diagnostic tools, the CRISPR-Cas system is being investigated for rapid and specific diagnosis of COVID-19. The CRISPR-Cas-based methods diagnose the SARS-CoV-2 infections within an hour. Apart from its diagnostic ability, CRISPR-Cas system is also being assessed for antiviral therapy development; however, till date, no CRISPR-based therapy has been approved for human use. The Prophylactic Antiviral CRISPR in huMAN cells (PAC-MAN), which is Cas 13 based strategy, has been developed against coronavirus. Although this strategy has the potential to be developed as a therapeutic modality, it may face significant challenges for approval in human clinical trials. This review is focused on describing potential use and challenges of CRISPR-Cas based approaches for the development of rapid and accurate diagnostic technique and/or a possible therapeutic alternative for combating COVID-19. The assessment of potential risks associated with use of CRISPR will be important for future clinical advancements.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.3389/fcimb.2020.576875
?:journal
  • Front_Cell_Infect_Microbiol
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/d2d9eda54d95a515d872bdb88baf6d418ddfa8db.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7673385.xml.json
?:pmcid
?:pmid
?:pmid
  • 33251158.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics
?:type
?:year
  • 2020-11-02

Metadata

Anon_0  
expand all